Mild Cognitive Impairment

Not so long ago, receiving a diagnosis of Alzheimer’s was a devastating piece of news. Usually, such a diagnosis came after specific symptoms of cognitive decline appeared. Physicians had little to offer beyond recommendations for getting your affairs in order (assuming you still had decision-making capacity when the diagnosis was…

Last summer, we reported on the FDA approval of Leqembi, a medication that slows down cognitive decline in patients with Mild Cognitive Impairment or early Alzheimer’s Disease. While the medication is now covered by Medicare, patients who want access still have to demonstrate a diagnosis of Alzheimer’s and still have…

As we’ve noted repeatedly, Alzheimer’s dementia is currently incurable and on the rise. While important strides have been made in diagnosing Alzheimer’s and in slowing down its progress in the early stages with new medications, we cannot reverse it. Therefore, our best defense against the ravages of Alzheimer’s is to…

There’s no doubt that we have entered an era when important opportunities will exist to delay or diminish the symptoms of dementia. As we’ve been covering in agebuzz, there is now a new drug (Leqembi) available to delay impairment and decline in patients with mild cognitive impairment or the early…

If you or a loved one suffers from mild cognitive impairment or have been diagnosed with early Alzheimer’s Disease, you’ve likely followed the news over the last few months about a new treatment awaiting FDA approval. Well, that FDA approval has arrived: Leqembi, a medication that targets the amyloid plaques…

Remarkably, no matter how much we report on the benefits of walking for both physical and cognitive health, new research continues to be published that enhances and strengthens our understanding of the value of walking for healthier aging. Whether it’s reducing your mortality risk, maintaining your cardiovascular health, or lifting…